|
|
Exchange: |
American Stock Exchange |
Security
Type: |
Common |
Shares
Out: |
135,340,000 |
Market
Cap: |
621.21(M) |
Last
Volume: |
11,363,101 |
Avg
Vol: |
11,331,682 |
52
Week Range: |
$1.94 - $5.59 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Co.'s primary program, molgramostim nebulizer solution is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor and is being developed for the treatment of autoimmune pulmonary alveolar proteinosis. Molgramostim nebulizer solution is administered once daily by inhalation via a nebulizer, the eFlow® Nebulizer System. The eFlow® Nebulizer System is a reusable electronic inhalation system. Molgramostim was also being investigated in cystic fibrosis (CF) and non-CF patients for the treatment of nontuberculous mycobacterial lung infection, a lung disorder.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
3,439,830 |
4,023,225 |
Total Buy Value |
$0 |
$0 |
$10,277,564 |
$11,106,809 |
Total People Bought |
0 |
0 |
12 |
12 |
Total Buy Transactions |
0 |
0 |
14 |
42 |
Total Shares Sold |
0 |
187,843 |
187,843 |
187,843 |
Total Sell Value |
$0 |
$885,322 |
$885,322 |
$885,322 |
Total People Sold |
0 |
3 |
3 |
3 |
Total Sell Transactions |
0 |
3 |
3 |
3 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Ramsay David A |
Director |
|
2021-12-15 |
4 |
B |
$1.08 |
$16,260 |
D/D |
15,000 |
1,426,142 |
2.39 |
3% |
|
Lowrance David L |
CHIEF FINANCIAL OFFICER |
|
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
138,793 |
|
- |
|
Chowdhury Badrul A. |
CHIEF MEDICAL OFFICER |
|
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
125,000 |
300,000 |
|
- |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2021-12-14 |
4 |
A |
$0.00 |
$0 |
D/D |
400,000 |
783,672 |
|
- |
|
Hawkins Richard J |
Director |
|
2021-12-13 |
4 |
OE |
$0.55 |
$400 |
D/D |
728 |
728 |
|
- |
|
Ramsay David A |
Director |
|
2021-12-10 |
4 |
B |
$1.04 |
$36,365 |
D/D |
35,000 |
1,411,142 |
2.39 |
18% |
|
Chowdhury Badrul A. |
CHIEF MEDICAL OFFICER |
|
2021-12-09 |
4 |
B |
$1.05 |
$26,250 |
D/D |
25,000 |
175,000 |
2.74 |
19% |
|
Ramsay David A |
Director |
|
2021-12-08 |
4 |
B |
$1.05 |
$13,815 |
D/D |
13,157 |
1,376,142 |
2.39 |
19% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2021-12-08 |
4 |
B |
$1.06 |
$6,889 |
D/D |
6,500 |
383,672 |
2.81 |
19% |
|
Ramsay David A |
Director |
|
2021-12-07 |
4 |
B |
$1.05 |
$12,400 |
D/D |
11,843 |
1,362,985 |
2.39 |
19% |
|
Elam Nevan C |
Director |
|
2021-12-06 |
4 |
OE |
$0.55 |
$645 |
D/D |
1,172 |
28,072 |
|
- |
|
Ramsay David A |
Director |
|
2021-09-30 |
4 |
B |
$1.30 |
$64,900 |
D/D |
50,000 |
1,101,142 |
2.39 |
-9% |
|
Ramsay David A |
Director |
|
2021-09-29 |
4 |
B |
$1.28 |
$60,658 |
D/D |
47,500 |
1,051,142 |
2.39 |
-1% |
|
Ramsay David A |
Director |
|
2021-09-28 |
4 |
B |
$1.29 |
$50,824 |
D/D |
39,552 |
1,003,642 |
2.39 |
-2% |
|
Elam Nevan C |
Director |
|
2021-08-18 |
4 |
OE |
$0.52 |
$1,190 |
D/D |
2,288 |
26,900 |
|
- |
|
Ramsay David A |
Director |
|
2021-08-18 |
4 |
B |
$1.18 |
$36,980 |
D/D |
30,736 |
964,090 |
2.39 |
5% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2021-08-18 |
4 |
B |
$1.19 |
$14,166 |
D/D |
11,900 |
345,022 |
2.81 |
5% |
|
Ramsay David A |
Director |
|
2021-08-17 |
4 |
B |
$1.18 |
$78,201 |
D/D |
66,554 |
933,354 |
2.39 |
8% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2021-08-17 |
4 |
B |
$1.18 |
$17,700 |
D/D |
15,000 |
333,122 |
2.81 |
8% |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2021-05-21 |
4 |
B |
$1.63 |
$16,298 |
D/D |
10,000 |
318,122 |
2.81 |
-19% |
|
Ramsay David A |
Director |
|
2021-05-19 |
4 |
B |
$1.58 |
$7,905 |
D/D |
5,003 |
866,800 |
2.39 |
-22% |
|
Ramsay David A |
Director |
|
2021-05-18 |
4 |
B |
$1.62 |
$81,100 |
D/D |
50,000 |
861,797 |
2.39 |
-20% |
|
Chowdhury Badrul A. |
CHIEF MEDICAL OFFICER |
|
2021-05-17 |
4 |
AS |
$1.56 |
$77,870 |
D/D |
(50,000) |
150,000 |
|
-19% |
|
Chowdhury Badrul A. |
CHIEF MEDICAL OFFICER |
|
2021-05-15 |
4 |
OE |
$0.00 |
$0 |
D/D |
200,000 |
200,000 |
|
- |
|
Pauls Matthew |
CHIEF EXECUTIVE OFFICER |
|
2021-04-19 |
4 |
AB |
$1.82 |
$49,871 |
D/D |
27,400 |
308,122 |
|
-24% |
|
179 Records found
|
|
Page 4 of 8 |
|
|